Analyst Price Target is $60.00
▲ +1,746.15% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Longeveron in the last 3 months. The average price target is $60.00, with a high forecast of $60.00 and a low forecast of $60.00. The average price target represents a 1,746.15% upside from the last price of $3.25.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Longeveron. This Buy consensus rating has held steady for over two years.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Read More